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Summary The bcl-2 gene encodes for a mitochondrial membrane proto-oncoprotein, the expression of which
is known to suppress programmed cell death (apoptosis). In the present study the prognostic value of bcl-2
proto-oncoprotein was immunohistochemically investigated in a series of 104 colorectal carcinomas. The bcl-2
staining patterns were semiquantitatively assessed and correlated with the pTNM stage, Dukes' classification,
lymphocytic infiltration (Jass classification) and tumour grade as well as parameters not.associated with
prognosis (gender, age, tumour site, histological tumour type). Statistical analysis was carried out using the
Kaplan-Meier method, the log-rank test, hazard ratios and their confidence intervals. Fifty-five out of 104
cases completely lacked immunohistochemical bcl-2 expression. Fewer than 5% of bcl-2-positive cells were
found in 25, 5-50% in 17 and more than 50% in five cases. The extent of bcl-2 expression by tumour cells
decreased significantly with respect to increasing tumour size (P<0.05), decreasing lymphocytic infiltration
(P<0.05) and chance of poor clinical outcome (P<0.05), but not with worsening of Dukes stages. In
multivariate analysis (Cox regression model) bcl-2 expression remained as an independent prognostic
parameter with Dukes' classification as stratification factor (P<0.001). Although the biological functions of
bcl-2 protein are not yet well understood, our results provide further evidence that bcl-2 oncoprotein appears
to be associated with favourable clinical outcome. Thus immunohistochemical bcl-2 phenotyping ofcolorectal
carcinoma may contribute in future to the clinical management of these patients.
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The bcl-2 gene encodes for a membrane-associated protein
that is present in outer mitochondrial membrane. Addi-
tionally it was described in some parts of the endoplasmatic
reticulum and nuclear envelope (Monaghan et al., 1992; Kra-
jewski et al., 1993; Jacobson et al., 1993). Expressed widely
during embryonic development, in the adult it is confined to
long-lived cells (e.g. stem cell populations, resting B lym-
phocytes, and peripheral neurones) (Hockenbery et al., 1991).
The biochemical function remains largely unknown, although
bcl-2 oncoprotein is known to inhibit programmed cell death
(for review see Reed, 1994). Furthermore some data support
a role in cell growth control via regulation of the redox
system of cells (Hockenbery et al., 1993; Kane et al., 1993;
Richter, 1993). Recently a paradoxical inhibition of in vitro
cell growth has been reported in several solid tumour cell
lines (Pietenpol et al., 1994).
The bcl-2 gene product was shown to be over-expressed in
the 14;18 translocation of human B-cell lymphoma (Tsu-
jimoto et al., 1985), Hodgkin's disease, and reactive lymph
nodes (Corbally et al., 1994) and was immunohistochemically
demonstrated in breast carcinoma (Doglioni et al., 1994;
Leek et al., 1994; Silvestrini et al., 1994), follicular carcinoma
of the thyroid (Pilotti et al., 1994a,b), non-small-cell lung
cancer (Pezzella et al., 1993), hepatocellular carcinoma (Zhao
et al., 1994) and neuroblastoma (Castle et al., 1993), but not
yet reported in colorectal cancer. In the present study 104
colorectal carcinomas were immunohistochemically inves-
tigated with a monoclonal antibody reactive against bcl-2
oncoprotein. The study was designed to assess the extent of
the immunohistochemical bcl-2 expression by tumour cells as
a possible prognostic parameter in colorectal cancer with
regard to patients' survival as well as histological grading
and staging parameters.
Patients and methods
Tumour tissues of 104 consecutive cases of colorectal
adenocarcinoma (40 rectal carcinomas, 43 carcinomas of the
left, and 21 of the right colon; 54 male, 50 female patients;
mean age 67.8 years, ranging from 35 to 90 years) were
investigated in this study. All patients had been operated
between 1984 and 1986 at the Department of Surgery I,
Innsbruck University Hospital, Austria, either with curative
(n = 87) or palliative intent (n = 17). None of these patients
died within 30 days after surgery, were treated with adjuvant
chemo- and/or radiotherapy or were members of families
with familial adenomatosis coli or hereditary non-polyposis
colorectal cancer.
Tumour tissues were routinely processed (formalin-fixed
and paraffin-embedded) and were classified according to
Dukes' classification (Dukes and Bussey, 1958), with an
added D-stage for patients with distant metastases, TNM
staging system (Spiessl et al., 1992) and WHO grading system
(Morson and Sobin, 1976). Lymphocytic infiltration at the
advancing edge of the tumour was determined according to
the criteria of Jass et al. (1986). Table I provides a detailed
description of staging and grading results. The mean follow-
up period of the 52 patients still alive until April 1994 was 79
months. The fate ofthe remaining three patients could not be
ascertained as they failed to comply with the follow-up
scheme.
Stainingprocedures
The commercially available monoclonal anti-bcl-2 antibody
124 (Dako, Copenhagen, Denmark) was applied to sections
that were pretreated with the wet autoclave method (Bank-
falvi et al., 1994) overnight at 4°C in a humidified chamber
[dilution in phosphate-buffered saline (PBS) containing 0.6%
bovine serum albumin 1:300], followed by a goat anti-mouse
bridging antibody (1:30 in PBS; 30 min at room temperature;
Dako) and a polyclonal mouse APAAP complex (1:100 in
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PBS; 60 min at room temperature; Dianova, Hamburg, Ger-
many). The bridging antibody and the APAAP complex were
applied on a semiautomatic immunostaining device ('Omni-
bus'; Quartett, Berlin, Germany). Subsequently the enzyme
reaction was developed for 25 min at room temperature in a
freshly prepared new fuchsin solution containing naphthol-
bi-as-phosphate. Finally the sections were counterstained
with haematoxylin and mounted in Kayser's glycerine
gelatine. Omission of the primary antibody and replacement
of the primary antibody by an inappropriate monoclonal
antibody were used for negative control, and normal human
tonsil tissues for positive control reactions.
Semiquantitative assessment ofimmunohistochemical staining
patterns
Semiquantitative evaluation was performed twice by one of
the authors (KWS) with a 2 week interval. The staining was
categorised as follows: no immunoreactive cells detectable
(neg), fewer than 5% bcl-2 (+), 5-50% of tumour cells
(+ +), and more than 50% (+ + +) positive cells. The
semiquantitative evaluation was shown to be highly rep-
roducible since no divergent diagnoses was made in the
second assessment.
Patients'follow-up andstatistical analysis
All data were entered into a Macintosh IIci microcomputer
and statistical analysis was carried out using the SYSTAT
statistical package (Wilkinson, 1989) including the SUR-
VIVAL supplementary module (Steinberg and Colla, 1988).
Patients were followed up according to the oncological
Table I Frequency of prognostic parameters investigated in 104
colorectal adenocarcinomas
Paramater No. Percentage
Tumour type
Intestinal 82 79
Mucinous 17 16
Signet ring cell 5 5
Histological grading
Well 14 13
Moderate 65 63
Poor 25 24
Lymphocytic infiltration
Mild 43 41
Moderate 46 44
Significant 15 15
Dukes' stage
A 9 9
B 48 46
C 30 29
D 17 16
pT stage
pTl 10 10
pT2 4 3
pT3 80 77
pT4 10 10
pN stage
pN0 54 52
pNl 13 12
pN2 20 19
pN3 5 5
pNx 12 12
M stage
MO 87 84
Ml 17 16
Tumour site
Right hemicolon 21 20
Left hemicolon 43 41
Rectum 40 39
Age
< 65 years 34 33
>65 years 70 67
Sex
Male 54 52
Female 50 48
follow-up scheme of the Department of Surgery I, University
of Innsbruck: clinical and laboratory examination (including
tumour marker CEA) were performed every 3 months within
the first 3 years, every 6 months in the 4th and 5th years
after surgery, and once a year afterwards. Colonoscopy or
barium enema and chest radiograph were performed accord-
ing to an obligatory protocol twice in years 1-3 and once a
year until year 5 after operation. Additionally the data conc-
erning the date and cause of death were confirmed by the
'Osterreichisches Statistiches Zentralamt', an institute of the
Austrian government. The cumulative patient survival was
estimated with the Kaplan-Meier method (Kaplan and
Meier, 1958); for comparison of the survival curves the log-
rank test was used (the Mantel-Haenszel method; Kalb-
fleisch and Prentice, 1980). The Cox proportional hazards
linear regression model (Cox, 1972), with Dukes' stages as a
stratification factor, was used to determine, in a forward
stepwise procedure, which factors were associated simult-
aneously with survival. Estimates of relative risks and 95%
confidence intervals (CI) were generated from the parameters
estimates of regression coefficients and associated standard
errors. Descriptive statistics for continuous measures are
given as the mean with the respective standard deviation in
parenthesis; discrete data frequency counts and percentages
are tabulated and groups were compared using chi-square
analysis with Yates' correction whenever appropriate.
Results
Immunostainingfor bcl-2protein
Fifty-five out of 104 cases (55%) investigated completely
lacked immunohistochemically detectable bcl-2. Less than
5% of bcl-2-positive cells were found in 25 (24%), 5-50% in
17 (16%), and more than 50% in five cases (5%) investigated
(Table II). In areas of normal colonic epithelium adjacent to
the tumour, bcl-2 expression was found in some basal cells.
Differentiated epithelial cells in the colonic mucosa were
constantly negative. A strong bcl-2 expression was found in
reactive lymphocytic cells. All negative controls constantly
lacked bcl-2 staining. Figure la-c depicts representative
immunohistochemical staining results.
Correlation ofbcl-2 expression with clinicopathological
parameters
The extent of bcl-2 expression by tumour cells decreased in a
statistically significant way [chi-square, 19.4; degrees of
freedom (DF), 9; P = 0.02; Table III] with increase in tumour
size (pT), but not Dukes' stages (total chi-square, 15.0; DF,
9; not significant). Tumour bcl-2 staining also increased
significantly with increasing lymphocytic infiltration at the
advancing edge of the tumour (total chi-square, 13.2; DF, 6;
P = 0.04) and chance of uneventful clinical outcome (total
chi-square, 13.6; DF, 6; P = 0.03). Table IV summarises all
correlations of bcl-2 expression to clinicopathological para-
meters available.
Univariate and multivariate long-term survival analysis
Figure 2 illustrates survival curves for all patients in the
study with regard to bcl-2-negative and -positive immuno-
Table II bcl-2 expression of 104 colorectal carcinomas with regard to
Dukes' classification
bcl-2 expression Dukes A Dukes B Dukes C Dukes D
neg 2 26 19 10
+ 5 11 5 4
++ 0 9 5 3
+++ 2 2 1 0
(Chi-square, 15.0; degrees of freedom, 9; not significant). Neg, no
immunoreactive cells detectable; +, less than 5% bcl-2; + +, 5-50%
tumour cells; + + + >50% positive cells.
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Table III bcl-2expression of 104colorectalcarcinomaswith regard to
pT stage
bcl-2 expression pTI(%) pT2(%) pT3(%) pT4(%)
neg 2 (20) 2 (50) 44 (55) 8 (80)
+ 5 (50) 0 (0) 18 (23) 2 (20)
++ 1(10) 1 (25) 16(20) 0
*+++ 2 (20) 1 (25) 2 (2) 0
(Chi-square, 19.4; degrees of freedom, 9; P = 0.02). Neg, no
immunoreactive cells detectable; +, less than 5% bcl-2; + +, 5-50%
tumour cells; + + +, 75% positive cells.
Table IV Correlation between bcl-2 and various clinicopathological
parameters investigated
Parameter Chi-square DF P
Dukes' classification 15.0 9 NS
pT stage 19.4 9 0.02
pN stagea 4.7 9 NS
M stage 1.1 3 NS
Histological tumour grade 7.7 6 NS
Tumour type 5.0 6 NS
Tumour site 4.1 6 NS
Lymphocytic infiltration 13.0 6 0.04
Age (< 65 years vs >65 years) 0.2 3 NS
Sex 6.0 3 NS
NS, notsignificant; DF, degrees offreedom. apNx cases(n = 13: four
Dukes A and nine Dukes D cases) excluded.
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Figure 2 Kaplan-Meier survival curves of 104 colorectal car-
cinomas with regard to bcl-2-positive and -negative immuno-
reactivity. Chi-square for the log-rank test (Mantel-Haenzel
method), 8.3; degrees of freedom, 1; P= 0.004. bcl-2
positive; ... bcl-2 negative.
Figure 1 (a) Well differentiated to moderately differentiated
colonic carcinoma with pronounced immunohistochemical bcl-2
expression. Note strong bcl-2 immunoreactivity of lymphocytes.
Normal colonic mucosa situated adjacent to the tumour lacks
bcl-2 (APAAP, x 100). (b) Less differentiated colonic carcinoma
with moderate cytoplasmic bcl-2 expression (APAAP, x 250). (c)
Well-differentiated colonic carcinoma lacks immunohistochemi-
cally detectable bcl-2, whereas bcl-2 can be demonstrated in
lymphocytes (APAAP, x 250).
reactivity. Univariate survival analysis of parameters
significantly associated with survival (Dukes' stage, pT stage,
pN stage, M-stage, lymphocytic infiltration, bcl-2 scores, his-
tological tumour grade) and variables which were not
associated with prognosis (sex, age, tumour site, histological
tumour type) are given in Table V. Multivariate analysis by
means of the Cox regression model using Dukes'
classification as a stratification factor (relative hazard rates
for patients with different Dukes' stages were not constant
over the follow-up intervals) revealed that bcl-2 immunoreac-
tivity was independently and statistically highly significantly
associated with survival (T-Stat, -3.1; P= 0.001). Addit-
ionally a marginal significance was found for the lymphocytic
infiltration (Jass classification; T-Stat, - 1.73; P = 0.05). All
other parameters which were significant by univariate app-
roach were rejected in multivariate analysis.
Discussion
Immunohistochemical phenotyping of tumours may provide
important information concerning tumour behaviour. Alt-
hough the known function of bcl-2 indicates a possible prog-
nostic role for this oncoprotein, only a few investigations
have compared immunohistochemically demonstrable bcl-2
protein with clinicopathological parameters. Our immuno-
histochemical results on tumours from patients with colorec-
tal carcinoma revealed a statistically significant association of
a
b
C
--- 9834
0.6
I I I I Ibc-2 expression in colorectal cancer op -D Ofner etal
984
Table V Prognostic factors examined in 104 colorectal carcinomas: a univariate
approach to cancer-specific mortality
Univariate X2for
the log-rank test DF p
Dukes' stage 84.8 3 0.0001
pT stage 17.3 3 0.001
pN stagea 30.5 4 0.0001
M stage 78.5 1 0.0001
bcl-2 expression (negative vs positive)b 8.3 1 0.004
Lymphocytic infiltrationb 8.6 2 0.01
Histological tumour grade 7.6 2 0.02
Type of tumour 4.1 3 NS
Tumour site 2.4 2 NS
Age (< 65 years vs >65 years) 0.0 I NS
Sex 0.0 I NS
apNx cases (n = 13: four Dukes A and nine Dukes D cases) excluded. bRemained
significant by Cox regression analysis. DF, degrees of freedom.
bcl-2 expression with favourable clinical outcome. Similar
results were previously reported on non-small-cell carcinomas
of the lung (Pezzella et al., 1993), breast carcinoma (Leek et
al., 1994) and thyroid follicular carcinomas (Pilotti et al.,
1994b). As in these tumours, the classic cause of bcl-2
overexpression, namely 14;18 translocation, has not been
found in colorectal carcinoma.
Our results showed that immunohistochemical bcl-2 dem-
onstration was significantly associated with the pT stage but
not with Dukes' classification or the development of lymph
node and organ metastases. bcl-2 was detectable in more
than 60% of cases with uneventful clinical course, whereas
the majority of cases with the development of metastases
(62%) and local recurrence (>90%) completely lacked
immunohistochemically detectable bcl-2 protein. These find-
ings support the concept that bcl-2 expression is related to
slower local tumour growth. Thus, the better clinical out-
come of these patients may simply be attributable to the
prolonged period over which these tumours remain clinically
detectable in their earlier stages of progression.
Normal tissues of organs with slow cell turnover rates are
known to express bcl-2 protein (Hockenbery et al., 1991;
Doglioni et al., 1994; Leek et al., 1994; Pilotti et al., 1994b).
In contrast to studies performed on carcinomas of the breast
(60%) and carcinomas derived from thyroid follicular
epithelium (approximately 80%), we found a considerably
lower percentage of positive immunoreactive cases in colorec-
tal cancer (45%). This most likely reflects biological
differences between these tumour types. It is intriguing to see
that, in contrast to the very advanced tumours of our series
of colorectal carcinomas expressing bcl-2 (<5%), bcl-2 was
detectable in more than 80% of poorly differentiated thyroid
carcinomas (Pilotti et al., 1994a).
In the studies on breast and thyroid carcinomas bcl-2
expression was shown to correlate with single favourable
prognostic parameters. However, in colorectal cancer a
statistically significant inverse association (P = 0.02; Table
III) between bcl-2 expression and tumour size was found.
Immunoreactivity for bcl-2 decreased from 80% (pTl
tumours) to 20% (pT4 tumours) with progressive tumour size
(compare Table III). Pezzella et al. (1993) found in their
study that survival of patients with bcl-2-positive non-small-
cell carcinomas (80 squamous-cell and 42 adenocarcinomas)
of the lung was statistically significantly higher. In colorectal
cancer a similar association (P = 0.03) of bcl-2 immunoreact-
ivity and clinical course of patients was found. Moreover it
was proven in our study, that immunohistochemically detec-
table bcl-2 expression predicts patient survival independently
in uni- and multivariate analysis (P = 0.001). Although of
minor statistical significance (P = 0.04), a correlation of
immunohistochemically demonstrated bcl-2 expression and
lymphocytic infiltration patterns at the advancing edge of the
tumour (Jass et al., 1986) was shown. Further research may
prove whether bcl-2 expression may be associated with the
biological background of lymphocytic infiltration.
Although the biological functions of bcl-2 protein are not
yet fully understood, the present findings provide further
evidence that immunohistochemically demonstrated bcl-2
oncoprotein appears to be associated with less aggressive
tumour behaviour and/or may reflect different stages of
tumour progression. However, it is not clear why bcl-2 exp-
ression seems to be associated with a favourable clinical
outcome. Pietenpol et al. (1994) found that expression of
bcl-2 in several solid tumour cell lines resulted in a paradox-
ical growth inhibition similar to that seen with p53. It has
been suggested that bcl-2-promoted cell survival in slowly
growing tumours may decrease the rate of acquiring comp-
lementary defects. Additionally bcl-2 oncoprotein regulates
cell growth not only by inhibition of programmed cell death
but also via the redox system of cells.
In summary we propose immunohistochemical bcl-2 exp-
ression to be an additional prognostic marker in colorectal
carcinoma. Immunohistochemically demonstrated bcl-2 may
even be an independent prognostic parameter with influence
on post-operative therapeutic strategies. However, further
research is necessary to elucidate the role of bcl-2 in cell and
tumour growth control.
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